Here, we show that the enhanced induction of tumor-specific KLRG1+CD8+ effector memory T cells in the blood, spleen, and tumors correlated with the better efficacy of the Vax/aGITR/aPD-1 treated groups against established melanoma tumors (Figures 1F and 6). Here, CD8A is linked to melanoma.